Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$432/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Globe Newswire News Releases

Sep 16, 2024 04:00 ET
c/side Raises $6M in Seed Funding to Thwart Costly Browser Supply Chain Attacks
c/side, a cybersecurity company with tools for monitoring, optimizing, and securing vulnerable browser-side third-party scripts, today announced $6 million in seed funding. The round is led by Uncork Capital, with participation from Mantis VC,...
Sep 16, 2024 04:00 ET
Certa Therapeutics Announces International Non-Proprietary Name for its First-in-class GPR68 Inhibitor Asengeprast (FT011)
Certa Therapeutics (Certa), a biotechnology company developing innovative precision therapies for patients with fibrotic diseases, today announces that its lead candidate FT011 has been granted the International Non-Proprietary Name (INN) of...
Sep 16, 2024 04:00 ET
Haleon Selects PubMatic as Supply Optimisation Partner to Enable More Effective, Sustainable Media Buying
PubMatic (NASDAQ:PUBM), an independent technology company delivering digital advertising’s supply chain of the future, today announced the launch of a new collaborative approach to supply path optimisation (SPO) for global healthcare company,...
Sep 16, 2024 04:00 ET
International Petroleum Corporation Announces Results of Normal Course Issuer Bid
International Petroleum Corporation (IPC or the Corporation) (TSX, Nasdaq Stockholm: IPCO) is pleased to announce that IPC repurchased a total of 197,200 IPC common shares (ISIN: CA46016U1084) during the period of September 9 to 13, 2024 under...
Sep 16, 2024 04:00 ET
PatientSeek identifies a genetic signature that separates a4b7 integrin therapy responder and non-responder populations in inflammatory bowel disease
C4X Discovery Holdings Limited PatientSeek identifies a genetic signature that separates a4b7 integrin therapy responder and non-responder populations in inflammatory bowel disease Progresses precision method for patient selection - the right...
Sep 16, 2024 03:58 ET
OKX Joins exSat as Key Validator to Enhance Bitcoin Scalability
OKX, a leading crypto exchange and global Web3 technology company, has issued updates for September 16, 2024. OKX Joins exSat as Key Validator to Enhance Bitcoin ScalabilityOKX today announced that it has joined exSat, a pioneering network...
Sep 16, 2024 03:18 ET
Kronos Advanced Technologies, Inc. (OTC: KNOS) Announces Ex-Dividend Date for Upcoming Special Cash Dividend
Los Angeles, CA September 16, 2024– Kronos Advanced Technologies, Inc. (OTC: KNOS), a leading innovator in advanced air purification technology, is pleased to announce that last Friday, after the markets closed, FINRA officially set the ex-dividend...
Sep 16, 2024 03:01 ET
Adagene Presents Results at ESMO Congress that Show Best-in-Class Therapeutic Potential for Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) in Combination with KEYTRUDA® (Pembrolizumab) in Advanced/Metastat
Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced new ADG126 clinical data presented at the ESMO Congress, taking place in Barcelona, Spain, September...
Sep 16, 2024 03:00 ET
Akur8 Secures $120 Million in Series C Round to Accelerate Growth of its Next Generation Actuarial Platform
Akur8, the machine learning-powered insurance pricing and reserving platform, announced today that it has secured $120 million in series C funding, bringing its total raised investment to $180 million. This latest funding round was led by One Peak,...
Sep 16, 2024 03:00 ET
Introducing THAT: Shifting from Cash to Innovation
In a bold move set to disrupt the financial landscape, THAT officially launches as a pioneering Layer-1 blockchain.  Designed to replace cash with a universally accessible cryptocurrency, THAT challenges the norm by targeting mass adoption...
Sep 16, 2024 03:00 ET
Nokia and NL-ix deploy Deepfield for the largest IXP-based anti-DDoS protection for enterprises across Europe
Press releaseNokia and NL-ix deploy Deepfield for the largest IXP-based anti-DDoS protection for enterprises across Europe A breakthrough case where an Internet Exchange Point (IXP) deploys a pan-European anti-DDoS solutionImproved DDoS protection...
Sep 16, 2024 02:00 ET
AAVantgarde announces first patient dosed in First-In-Human Phase 1/2 LUCE-1 study, evaluating AAVB-081 (Dual-AAV) in retinitis pigmentosa related to Usher Syndrome type 1B
AAVantgarde Bio (AAVantgarde), an Italy-based global biotechnology company, announced that the first subject has been dosed in the LUCE-1 trial, a Phase 1/2 open label clinical trial to assess safety and tolerability of AAVB-081, using the...
Sep 16, 2024 02:00 ET
MaxCyte Signs Strategic Platform License with Kamau Therapeutics to Accelerate the Development of Cell Therapies for Genetic Diseases
MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and innovative...
Sep 16, 2024 02:00 ET
OKX Wallet and Uniswap Labs to Host 'Swap to the Future' Exhibition Event in Singapore
OKX, a global Web3 technology company, has issued updates for September 16, 2024. OKX Wallet Team and Uniswap Labs to Host 'Swap to the Future' Exhibition Event in SingaporeOKX Wallet and Uniswap Labs are set to host an exhibition event titled...
Sep 16, 2024 01:30 ET
Vallourec Enhances Its Line Pipe Coating Solutions With the Acquisition of Thermotite do Brasil
VALLOUREC ENHANCES ITS LINE PIPE COATING SOLUTIONS WITH THE ACQUISITION OF THERMOTITE DO BRASIL Meudon (France), September 16, 2024 – Vallourec, a world leader in premium seamless tubular solutions, has entered into a definitive agreement to...
Sep 16, 2024 01:00 ET
China patent notification boosts PolTREG’s development of Treg cell therapy in multiple sclerosis
China’s National Intellectual Property Administration has issued notification to grant patent to PolTREG Chinese patent covers intrathecal administration of PolTREG’s PTG-007 Treg cell therapy to treat multiple sclerosisIntrathecal administration...
Sep 15, 2024 21:00 ET
Vera Bradley Foundation for Breast Cancer Raises $1,601,830 for Breast Cancer Research
The Vera Bradley Foundation for Breast Cancer (the "Foundation") today announced a donation of $1,601,830 to support the Vera Bradley Foundation Center for Breast Cancer Research at the Indiana University School of Medicine (“IU School of...
Sep 15, 2024 16:04 ET
MacroGenics (MGNX) Investors Alerted to September 24th Deadline in Securities Class Action, Encouraged to Contact Hagens Berman
Hagens Berman urges MacroGenics, Inc. (NASDAQ: MGNX) investors who suffered substantial losses to submit your losses now. Class Period: Mar. 7, 2024 – May 9, 2024Lead Plaintiff Deadline: Sept. 24, 2024 Visit: www.hbsslaw.com/investor-fraud/mgnx...
Sep 15, 2024 16:00 ET
AGEN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Agenus Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Agenus Inc. (“Agenus” or “the Company”) (NASDAQ: AGEN) and certain of its officers....
Sep 15, 2024 16:00 ET
CAL INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Caleres, Inc. and Encourages Investors to Contact the Firm!
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Caleres, Inc. (“Caleres” or “the Company”) (NYSE: CAL). Investors who purchased Caleres securities are encouraged to obtain...